This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Asia
20 - 22 October, 2025
Presented in Japan Standard TimeThe Westin Miyako Kyoto

Delivered as a Hybrid Event

20 - 22 October, 2025
Presented in Japan Standard Time,
The Westin Miyako Kyoto

Delivered as a Hybrid Event

Asia's leading conference to accelerate antibody/protein therapeutics, ADCs, Bispecifics & Immuno-oncology

Bringing together the antibody/protein therapeutic community to share advances in antibody discovery & engineering, bi/multispecific antibodies, ADCs, immuno-oncology & AI/ML-enabled applications

Select the right antibody, move faster towards IND, and apply clinical learnings from real-world case studies.

HAVE YOUR SAY, GET AN EXCLUSIVE DISCOUNT!

Would you like to speak at the 2025 event? Have you got topics or speakers in mind that you would like us to bring to Japan? Have your say in shaping the agenda for the return of Antibody Engineering & Therapeutics Asia 2025, or register your interest so you don't miss any updates, by completing the form below. Plus, by registering via the form you will get early-access to the agenda - as well as a discount on your pass!

New Data, Case Studies & Networking with Antibody Experts

What to expect?

Join industry pioneers as they explore the latest breakthroughs in the antibody community and dive into:

  • Bispecific and Multispecific Antibodies
  • Antibodies for Novel/Challenging Targets
  • Immune Cell Engager Antibody Technologies
  • Antibody-Drug Conjugates
  • Disease-Area Specific Antibodies
  • AI/Machine Learning for Antibody Developability
  • New Binders, Therapeutic Modalities & Antibody Formats
  • Agonist Antibodies and Conditional Antibodies
  • Novel Antibody Technologies and Applications
  • Preclinical and Clinical Antibody Case Studies


Plus, enhance your experience with two workshop add-ons:

  • Introduction to Antibody Engineering (AM)
  • Introduction to Bispecific & Multispecific Antibodies (PM)
Training Course: Introduction to Antibody Engineering

Who will you meet?

Dedicated to connect you with 200+ leaders including:

  • Renowned industry and academic scientists specializing in antibody and protein engineering.
  • Experts in therapeutic development sharing the latest preclinical and clinical data on antibodies, ADCs, bispecifics, and immuno-oncology programs.
  • Innovators presenting cutting-edge advances in antibody-related technologies from around the world.
  • Potential partners to help accelerate your next-generation antibodies towards commercial success.

35+ expert speakers

Hear from the leading antibody companies in the field from the US, Europe and APAC. Prepare to be inspired by keynote speakers.

Gain in-depth insights from the leading minds in antibody and protein therapeutics. Discover the latest advancements in antibody discovery, engineering, bispecifics, ADCs, and immuno-oncology, including AI/ML applications.

Leave with confidence to select the right antibodies, accelerate your path to IND, and apply clinical insights from real-world case studies to drive your success.

Connect with key buyers at Antibody Asia 2025

Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.

Contact Blake Shuka to find out you can get involved:
BShuka@informaconnectls.com | (+1) 212-600-3451

In 2024 we brought you:

+

Antibody Experts

+

Leading Speakers

+

Hours of Scientific Content

Hours

of Networking

Watch the 2024 Highlights

Take a peek at the key moments, groundbreaking presentations, and vibrant networking sessions from Antibody Engineering & Therapeutics Asia. Back again for 2025, now’s your chance to see why this is the premier event driving antibody innovation in the Asia-Pacific region.